A national study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs with the potential to interrupt disease progression. A national study ...

Numerous strategies have been used, including repurposing existing antivirals or drugs used in previous viral outbreaks. One such strategy is to repurpose FDA-approved kinase inhibitors that are ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim d ...

There are many assets with many different mechanism of actions going into the EGFR development pipeline, which is quite exciting. The most advanced, I will say, have to be antibody drug conjugates.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

BRANFORD, Conn. - Azitra, Inc. (NYSE American: AZTR), a biopharmaceutical company specializing in precision dermatology ...

In this video, Xiuning Le, MD, PhD, discusses how she approaches putting together a treatment plan for a patient with EGFR-mutated lung cancer.

A national study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs with the potential to interrupt disease progression. Houston Methodist and ...

The molecular basis and mechanisms of action of combining classic cytotoxic agents (e.g. platinum-containing drugs, taxanes, etc.) and novel agents (e.g. tirapazamine, EGFR inhibitors and other ...